Review





Similar Products

96
ATCC growth hormone adenoma cell line gh3
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Growth Hormone Adenoma Cell Line Gh3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/growth hormone adenoma cell line gh3/product/ATCC
Average 96 stars, based on 1 article reviews
growth hormone adenoma cell line gh3 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

96
TargetMol t2154 cat 133407 82 6
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
T2154 Cat 133407 82 6, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t2154 cat 133407 82 6/product/TargetMol
Average 96 stars, based on 1 article reviews
t2154 cat 133407 82 6 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

96
ATCC β glucosidse cazy gh 3
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
β Glucosidse Cazy Gh 3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β glucosidse cazy gh 3/product/ATCC
Average 96 stars, based on 1 article reviews
β glucosidse cazy gh 3 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

96
ATCC bacteroides ovatus atcc 8483
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Bacteroides Ovatus Atcc 8483, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bacteroides ovatus atcc 8483/product/ATCC
Average 96 stars, based on 1 article reviews
bacteroides ovatus atcc 8483 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

95
ATCC gh3 cells
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Gh3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gh3 cells/product/ATCC
Average 95 stars, based on 1 article reviews
gh3 cells - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

95
ATCC gh1 cells
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Gh1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gh1 cells/product/ATCC
Average 95 stars, based on 1 article reviews
gh1 cells - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

94
PCR Biosystems Ltd clara probe 1 step mix lo rox kit
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Clara Probe 1 Step Mix Lo Rox Kit, supplied by PCR Biosystems Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clara probe 1 step mix lo rox kit/product/PCR Biosystems Ltd
Average 94 stars, based on 1 article reviews
clara probe 1 step mix lo rox kit - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

95
ATCC gh3 epithelial like rat pituitary tumor cell line
DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Gh3 Epithelial Like Rat Pituitary Tumor Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gh3 epithelial like rat pituitary tumor cell line/product/ATCC
Average 95 stars, based on 1 article reviews
gh3 epithelial like rat pituitary tumor cell line - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Journal: Redox Biology

Article Title: p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas

doi: 10.1016/j.redox.2026.104077

Figure Lengend Snippet: DA downregulates p300 expression by inhibiting the cAMP/PKA/CREB pathway in pituitary tumor cells. (A) Correlation analysis was performed between the percentage reduction in tumor maximum diameter and the percentage decrease in serum prolactin (PRL) levels before and after bromocriptine (BRC) treatment in 86 patients with drug-resistant prolactinomas. Patients were classified into a relatively sensitive group (n = 43) and a relatively insensitive group (n = 43). (B) Immunohistochemistry (IHC) staining was used to detect p300 expression in the above two groups of patients. (C) IHC staining was performed to detect p300 expression in the BRC-untreated group (n = 32) and BRC-treated group (n = 86). (D) Representative IHC staining images of p300 in the BRC-untreated group, relatively sensitive group, and relatively insensitive group. (E) Correlation analysis was conducted between the total BRC dosage administered and p300 expression in 86 treated patients. (F) Flowchart showing the establishment of an orthotopic pituitary prolactinoma model in rats. (G) Representative images of successfully established orthotopic pituitary prolactinoma in rats. (H–I) After successful establishment of orthotopic pituitary prolactinoma in rats, the rats were intraperitoneally (i.p.) injected with PBS, BRC (10 mg/kg/d), or cabergoline (CAB, 15 mg/kg/d) for 2 weeks. Immunofluorescence (IF) staining was used to detect p300 expression levels in tumor tissues (n = 4). (J-K) Western blot (WB) analysis was performed to detect nuclear p300 expression in MMQ and PA cells treated with BRC (0, 5, 10 μM) or CAB (0, 12.5, 25 μM) for 48 h (n = 3). (L-M) WB analysis was used to detect nuclear p300 expression in MMQ and PA cells treated with BRC (10 μM) or CAB (25 μM) for different durations (0, 24, 48 h) (n = 3). MMQ and PA cells were treated with BRC (10 μM), CAB (25 μM), forskolin (FSK, 50 μM), BRC (10 μM) + FSK (50 μM), or CAB (25 μM) + FSK (50 μM) for 48 h. (N–O) Intracellular cyclic adenosine monophosphate (cAMP) concentrations in MMQ and PA cells were detected using a cAMP ELISA kit (n = 5). (P-Q) WB analysis was performed to detect the expression of total protein kinase A catalytic subunit (PKA-C), total cAMP response element-binding protein (t-CREB), phosphorylated CREB ( p -CREB), CREB-binding protein (CBP), and p300 in MMQ and PA cells (n = 3). (R) Schematic diagram of the cAMP/PKA/CREB/p300 signaling pathway mediated by DA acting on dopamine D2 receptors (DRD2). Pearson correlation analysis was used for correlation between two variables. Independent sample t -test was used for comparison between two groups. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: Rat prolactinoma cell line MMQ, growth hormone adenoma cell line GH3, and mouse corticotropin adenoma cell line AtT-20 were obtained from the American Type Culture Collection (ATCC).

Techniques: Expressing, Immunohistochemistry, Injection, Immunofluorescence, Staining, Western Blot, Enzyme-linked Immunosorbent Assay, Binding Assay, Comparison

Upregulation of p300 synergizes with DA to promote cell apoptosis by increasing mitochondrial ROS in pituitary tumor cells. (A-B) Cell Counting Kit-8 (CCK-8) assay was used to detect cell viability in MMQ and AtT-20 cells transfected with empty vector or p300 overexpression plasmid (OE-p300) treated with BRC (10 μM) for different durations (0, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48 h) (n = 3). (C-D) CCK-8 assay was used to detect cell viability in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) or CAB (25 μM) for 48 h (n = 5). (E) AtT-20 cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for 24 h, followed by bulk RNA sequencing and KEGG pathway enrichment analysis of differentially upregulated genes (n = 3). (F–I) Flow cytometry was used to detect mitochondrial ROS levels in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) or CAB (25 μM) for 48 h. Flow cytometry was used to detect mitochondrial ROS levels in PA cells treated with BRC (10 μM), CAB (25 μM), N-(4-chloro-3-triffuoromethyl-phenyl)-2- ethoxy-benzamide (CTB, 50 μM), BRC (10 μM) + CTB (50 μM), or CAB (25 μM) + CTB (50 μM) for 48 h (n = 3). (J-L) Flow cytometry was used to detect cell apoptosis levels in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) alone or combined with N-acetylcysteine (NAC, 5 mM) or glutathione (GSH, 2 mM) for 48 h (n = 3). (M) Schematic diagram of molecular structures of wild-type p300 and histone acetyltransferase (HAT) domain-mutated p300. (N–S) Flow cytometry was used to detect mitochondrial ROS levels and apoptosis levels in MMQ and AtT-20 cells (transfected with empty vector, wild-type p300 overexpression plasmid [OE-WT-p300], or HAT domain-mutated p300 overexpression plasmid [OE-Mut-p300]) treated with BRC (10 μM) for 48 h (n = 3). One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Journal: Redox Biology

Article Title: p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas

doi: 10.1016/j.redox.2026.104077

Figure Lengend Snippet: Upregulation of p300 synergizes with DA to promote cell apoptosis by increasing mitochondrial ROS in pituitary tumor cells. (A-B) Cell Counting Kit-8 (CCK-8) assay was used to detect cell viability in MMQ and AtT-20 cells transfected with empty vector or p300 overexpression plasmid (OE-p300) treated with BRC (10 μM) for different durations (0, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48 h) (n = 3). (C-D) CCK-8 assay was used to detect cell viability in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) or CAB (25 μM) for 48 h (n = 5). (E) AtT-20 cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for 24 h, followed by bulk RNA sequencing and KEGG pathway enrichment analysis of differentially upregulated genes (n = 3). (F–I) Flow cytometry was used to detect mitochondrial ROS levels in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) or CAB (25 μM) for 48 h. Flow cytometry was used to detect mitochondrial ROS levels in PA cells treated with BRC (10 μM), CAB (25 μM), N-(4-chloro-3-triffuoromethyl-phenyl)-2- ethoxy-benzamide (CTB, 50 μM), BRC (10 μM) + CTB (50 μM), or CAB (25 μM) + CTB (50 μM) for 48 h (n = 3). (J-L) Flow cytometry was used to detect cell apoptosis levels in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) alone or combined with N-acetylcysteine (NAC, 5 mM) or glutathione (GSH, 2 mM) for 48 h (n = 3). (M) Schematic diagram of molecular structures of wild-type p300 and histone acetyltransferase (HAT) domain-mutated p300. (N–S) Flow cytometry was used to detect mitochondrial ROS levels and apoptosis levels in MMQ and AtT-20 cells (transfected with empty vector, wild-type p300 overexpression plasmid [OE-WT-p300], or HAT domain-mutated p300 overexpression plasmid [OE-Mut-p300]) treated with BRC (10 μM) for 48 h (n = 3). One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: Rat prolactinoma cell line MMQ, growth hormone adenoma cell line GH3, and mouse corticotropin adenoma cell line AtT-20 were obtained from the American Type Culture Collection (ATCC).

Techniques: Cell Counting, CCK-8 Assay, Transfection, Plasmid Preparation, Over Expression, RNA Sequencing, Flow Cytometry, Comparison

Upregulation of p300 synergizes with DA to promote histone H3K18 lactylation in pituitary tumor cells. (A) Transmission electron microscopy (TEM) was used to observe mitochondrial morphological changes in MMQ cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 48 h, the structures indicated by the red arrows are the mitochondria. (n = 3). (B) MMQ cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for 48 h, followed by detection of extracellular acidification rate (ECAR) using a Seahorse cell energy metabolism assay. (C) Glycolytic baseline and glycolytic capacity were calculated based on ECAR (n = 3). (D-G) MMQ and AtT-20 cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for different durations (0, 3, 6, 12, 18, 24, 48, 72 h). (D, F) Intracellular lactic acid and acetyl-CoA in MMQ and AtT-20 cells were detected using a lactic acid detection kit and acetyl-CoA detection kit, and the OE-p300 group at each time point was normalized using the Vec + BRC group (

Journal: Redox Biology

Article Title: p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas

doi: 10.1016/j.redox.2026.104077

Figure Lengend Snippet: Upregulation of p300 synergizes with DA to promote histone H3K18 lactylation in pituitary tumor cells. (A) Transmission electron microscopy (TEM) was used to observe mitochondrial morphological changes in MMQ cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 48 h, the structures indicated by the red arrows are the mitochondria. (n = 3). (B) MMQ cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for 48 h, followed by detection of extracellular acidification rate (ECAR) using a Seahorse cell energy metabolism assay. (C) Glycolytic baseline and glycolytic capacity were calculated based on ECAR (n = 3). (D-G) MMQ and AtT-20 cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for different durations (0, 3, 6, 12, 18, 24, 48, 72 h). (D, F) Intracellular lactic acid and acetyl-CoA in MMQ and AtT-20 cells were detected using a lactic acid detection kit and acetyl-CoA detection kit, and the OE-p300 group at each time point was normalized using the Vec + BRC group ("nc" in the figure) from the corresponding time point. (E, G) The ratios of lactic acid to acetyl-CoA contents in MMQ and AtT-20 cells were calculated separately (n = 3). (H–I) WB analysis was used to detect pan lactyl-lysine and pan acetyl-lysine protein expression in MMQ (H) and AtT-20 (I) cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 24 h or 48 h (n = 3). (J) WB analysis was used to detect pan lactyl-lysine and pan acetyl-lysine protein expression in PA cells treated with BRC (10 μM) or BRC (10 μM) + CTB (50 μM) for 24 h or 48 h (n = 3). (K-L) WB analysis was used to detect H3K18 lactylation (H3K18la) expression in MMQ and AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) or CAB (25 μM) for 48 h (n = 3). (M) WB analysis was used to detect H3K18la expression in PA cells treated with BRC (10 μM), CAB (25 μM), CTB (50 μM), BRC (10 μM) + CTB (50 μM), or CAB (25 μM) + CTB (50 μM) for 48 h (n = 3). (N) Schematic diagram of molecular structures of wild-type p300 and HAT domain-mutated p300. (O) WB analysis was used to detect H3K18la expression in MMQ and AtT-20 cells (transfected with empty vector, OE-WT-p300, or OE-Mut-p300) treated with BRC (10 μM) for 48 h (n = 3). (P) Co-IP experiments were performed using anti-p300 antibodies in MMQ and AtT-20 cells (transfected with OE-WT-p300 or OE-Mut-p300) treated with BRC (10 μM) for 48 h, followed by WB analysis to detect H3K18la expression (n = 3). One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: Rat prolactinoma cell line MMQ, growth hormone adenoma cell line GH3, and mouse corticotropin adenoma cell line AtT-20 were obtained from the American Type Culture Collection (ATCC).

Techniques: Transmission Assay, Electron Microscopy, Transfection, Plasmid Preparation, Expressing, Co-Immunoprecipitation Assay, Comparison

Upregulation of p300 synergizes with DA to elevate mitochondrial ROS levels via H3K18la-mediated transcription of Ndufs7 and Washc1 in pituitary tumor cells. (A-D) AtT-20 cells (transfected with empty vector or OE-p300) were treated with sodium lactate (5 mM) or BRC (10 μM) for 24 h, followed by bulk RNA sequencing. (A) Volcano plot showing the distribution of differentially expressed genes in the vector + sodium lactate group (Vec + L-Na) compared with the vector group (Vec). (B) Volcano plot showing the distribution of differentially expressed genes in the OE-p300+BRC group compared with the Vec + BRC group. (C) Venn diagram of the intersection of upregulated differentially expressed genes from groups A and B. (D) KEGG pathway enrichment of the 2273 genes obtained from the intersection in C (n = 3). (E) Peak plot showing H3K18la enrichment in genome-wide promoter regions of cells from the OE-p300+BRC group and Vec + BRC group in AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 24 h. (F) Venn diagram of the intersection between the 2273 genes obtained from the intersection in C and the upregulated differentially expressed genes enriched by CUT&Tag using anti-H3K18la antibody in AtT-20 cells (transfected with OE-p300) treated with BRC (10 μM) for 24 h. (G) Venn diagram of the intersection between the 36 genes obtained from the intersection in F and the ROS-related gene set (KEGG: mmu05208). (H) Peak plot showing H3K18la enrichment in the NADH dehydrogenase [ubiquinone] Fe–S protein 7 (Ndufs7) promoter region in the Vec + BRC group and OE-p300+BRC group in AtT-20 cells. (I) Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) of H3K18la enrichment in the Ndufs7 promoter region in the Vec + BRC group, OE-p300+BRC group, and OE-p300+BRC + Gal group in AtT-20 cells (n = 3). AtT-20 cells in the vector group were treated with BRC (10 μM) or BRC (10 μM) + CTB (50 μM) for 48 h. AtT-20 cells in the OE-p300 group, OE-p300 with Ndufs7 knockdown group 1 (sh1+OE), and OE-p300 with Ndufs7 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 48 h, followed by flow cytometry to detect mitochondrial ROS levels (J), hydrogen peroxide detection kit to measure intracellular hydrogen peroxide levels (K), and flow cytometry to detect cell apoptosis levels (L) (n = 3). (M) After AtT-20 cells in the vector group, OE-p300 group, OE-p300 with Ndufs7 knockdown group 1 (sh1+OE), and OE-p300 with Ndufs7 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 36 h, electron leak was detected via high-resolution respirometry combined with fluorometry (n = 3). (N) AtT-20 cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for 24 h, followed by bulk RNA sequencing and KEGG pathway enrichment analysis of differentially downregulated genes (n = 3). (O) TEM was used to observe mitochondrial morphological changes in AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 24 h, the process indicated by the red arrows is mitophagy. (n = 3). (P) Venn diagram of the intersection between the 36 genes obtained from the intersection in F and the autophagy-related gene set (GO:0010506). (Q) Peak plot showing H3K18la enrichment in the WASH complex subunit 1 (Washc1) promoter region in the vector group and OE-p300+BRC group in AtT-20 cells. (R) ChIP-qPCR of H3K18la enrichment in the Washc1 promoter region in the Vec + BRC group, OE-p300+BRC group, and OE-p300+BRC + Gal group in AtT-20 cells (n = 3). AtT-20 cells in the vector group were treated with BRC (10 μM) or BRC (10 μM) + CTB (50 μM) for 48 h. AtT-20 cells in the OE-p300 group, OE-p300 with Washc1 knockdown group 1 (sh1+OE), and OE-p300 with Washc1 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 48 h, followed by flow cytometry to detect mitochondrial ROS levels (S), hydrogen peroxide detection kit to measure intracellular hydrogen peroxide levels (T), and flow cytometry to detect cell apoptosis levels (U) (n = 3). (V) Schematic diagram showing that NDUFS7 increases mitochondrial ROS and WASH1 inhibits mitophagy, thereby inducing cell apoptosis. One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Journal: Redox Biology

Article Title: p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas

doi: 10.1016/j.redox.2026.104077

Figure Lengend Snippet: Upregulation of p300 synergizes with DA to elevate mitochondrial ROS levels via H3K18la-mediated transcription of Ndufs7 and Washc1 in pituitary tumor cells. (A-D) AtT-20 cells (transfected with empty vector or OE-p300) were treated with sodium lactate (5 mM) or BRC (10 μM) for 24 h, followed by bulk RNA sequencing. (A) Volcano plot showing the distribution of differentially expressed genes in the vector + sodium lactate group (Vec + L-Na) compared with the vector group (Vec). (B) Volcano plot showing the distribution of differentially expressed genes in the OE-p300+BRC group compared with the Vec + BRC group. (C) Venn diagram of the intersection of upregulated differentially expressed genes from groups A and B. (D) KEGG pathway enrichment of the 2273 genes obtained from the intersection in C (n = 3). (E) Peak plot showing H3K18la enrichment in genome-wide promoter regions of cells from the OE-p300+BRC group and Vec + BRC group in AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 24 h. (F) Venn diagram of the intersection between the 2273 genes obtained from the intersection in C and the upregulated differentially expressed genes enriched by CUT&Tag using anti-H3K18la antibody in AtT-20 cells (transfected with OE-p300) treated with BRC (10 μM) for 24 h. (G) Venn diagram of the intersection between the 36 genes obtained from the intersection in F and the ROS-related gene set (KEGG: mmu05208). (H) Peak plot showing H3K18la enrichment in the NADH dehydrogenase [ubiquinone] Fe–S protein 7 (Ndufs7) promoter region in the Vec + BRC group and OE-p300+BRC group in AtT-20 cells. (I) Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) of H3K18la enrichment in the Ndufs7 promoter region in the Vec + BRC group, OE-p300+BRC group, and OE-p300+BRC + Gal group in AtT-20 cells (n = 3). AtT-20 cells in the vector group were treated with BRC (10 μM) or BRC (10 μM) + CTB (50 μM) for 48 h. AtT-20 cells in the OE-p300 group, OE-p300 with Ndufs7 knockdown group 1 (sh1+OE), and OE-p300 with Ndufs7 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 48 h, followed by flow cytometry to detect mitochondrial ROS levels (J), hydrogen peroxide detection kit to measure intracellular hydrogen peroxide levels (K), and flow cytometry to detect cell apoptosis levels (L) (n = 3). (M) After AtT-20 cells in the vector group, OE-p300 group, OE-p300 with Ndufs7 knockdown group 1 (sh1+OE), and OE-p300 with Ndufs7 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 36 h, electron leak was detected via high-resolution respirometry combined with fluorometry (n = 3). (N) AtT-20 cells (transfected with empty vector or OE-p300) were treated with BRC (10 μM) for 24 h, followed by bulk RNA sequencing and KEGG pathway enrichment analysis of differentially downregulated genes (n = 3). (O) TEM was used to observe mitochondrial morphological changes in AtT-20 cells (transfected with empty vector or OE-p300) treated with BRC (10 μM) for 24 h, the process indicated by the red arrows is mitophagy. (n = 3). (P) Venn diagram of the intersection between the 36 genes obtained from the intersection in F and the autophagy-related gene set (GO:0010506). (Q) Peak plot showing H3K18la enrichment in the WASH complex subunit 1 (Washc1) promoter region in the vector group and OE-p300+BRC group in AtT-20 cells. (R) ChIP-qPCR of H3K18la enrichment in the Washc1 promoter region in the Vec + BRC group, OE-p300+BRC group, and OE-p300+BRC + Gal group in AtT-20 cells (n = 3). AtT-20 cells in the vector group were treated with BRC (10 μM) or BRC (10 μM) + CTB (50 μM) for 48 h. AtT-20 cells in the OE-p300 group, OE-p300 with Washc1 knockdown group 1 (sh1+OE), and OE-p300 with Washc1 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 48 h, followed by flow cytometry to detect mitochondrial ROS levels (S), hydrogen peroxide detection kit to measure intracellular hydrogen peroxide levels (T), and flow cytometry to detect cell apoptosis levels (U) (n = 3). (V) Schematic diagram showing that NDUFS7 increases mitochondrial ROS and WASH1 inhibits mitophagy, thereby inducing cell apoptosis. One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: Rat prolactinoma cell line MMQ, growth hormone adenoma cell line GH3, and mouse corticotropin adenoma cell line AtT-20 were obtained from the American Type Culture Collection (ATCC).

Techniques: Transfection, Plasmid Preparation, RNA Sequencing, Genome Wide, Chromatin Immunoprecipitation, Real-time Polymerase Chain Reaction, ChIP-qPCR, Knockdown, Flow Cytometry, Comparison

WASH1 inhibits mitophagy by binding to the ubiquitin-associated (UBA) domain of p62 in pituitary tumor cells. (A) MMQ and AtT-20 cells in the vector group, OE-p300 group, OE-p300 with Washc1 knockdown group 1 (sh1+OE), and OE-p300 with Washc1 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 48 h, followed by WB analysis to detect the expression of LC3BI/II, p62, translocase of outer mitochondrial membrane 20 (TOM20), translocase of inner mitochondrial membrane 23 (TIM23), and cytochrome c oxidase subunit IV (COX IV) (n = 3). (B) WASH1-Flag protein was overexpressed in AtT-20 cells with Washc1 knockout, and immunoprecipitation-mass spectrometry (IP-MS) was used to analyze potential interacting proteins of WASH1. (C) Mouse WASH1 protein and the UBA domain of p62 were subjected to molecular docking using the HDOCK server ( http://hdock.phys.hust.edu.cn/ ). Appropriate prediction models were selected, and docking results were analyzed using PyMOL (Version 3.1). (D) In MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout, wild-type Washc1 (OE-WT-Flag) or mutant Washc1 (OE-Mut-Flag) was then overexpressed. Co-IP experiments were conducted using anti-Flag antibodies, and subsequent WB analysis was used to detect the expression of WASH1-Flag and p62 (n = 3). (E) MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 48 h, followed by WB analysis to detect the expression of LC3BI/II, p62, TOM20, TIM23, and COX IV (n = 3). (F) MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 24 h, followed by mt-Keima ratiometric analysis to quantify mitophagy levels (n = 4). (G) MMQ and AtT-20 cells in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 24 h, and confocal fluorescence microscopy was used to observe the co-localization of mitochondria (TOM20) and lysosomes (lysosome-associated membrane protein 1, LAMP1) (n = 3). (H–I) MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 48 h, followed by flow cytometry to detect mitochondrial ROS and cell apoptosis levels (n = 3). One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Journal: Redox Biology

Article Title: p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas

doi: 10.1016/j.redox.2026.104077

Figure Lengend Snippet: WASH1 inhibits mitophagy by binding to the ubiquitin-associated (UBA) domain of p62 in pituitary tumor cells. (A) MMQ and AtT-20 cells in the vector group, OE-p300 group, OE-p300 with Washc1 knockdown group 1 (sh1+OE), and OE-p300 with Washc1 knockdown group 2 (sh2+OE) were treated with BRC (10 μM) for 48 h, followed by WB analysis to detect the expression of LC3BI/II, p62, translocase of outer mitochondrial membrane 20 (TOM20), translocase of inner mitochondrial membrane 23 (TIM23), and cytochrome c oxidase subunit IV (COX IV) (n = 3). (B) WASH1-Flag protein was overexpressed in AtT-20 cells with Washc1 knockout, and immunoprecipitation-mass spectrometry (IP-MS) was used to analyze potential interacting proteins of WASH1. (C) Mouse WASH1 protein and the UBA domain of p62 were subjected to molecular docking using the HDOCK server ( http://hdock.phys.hust.edu.cn/ ). Appropriate prediction models were selected, and docking results were analyzed using PyMOL (Version 3.1). (D) In MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout, wild-type Washc1 (OE-WT-Flag) or mutant Washc1 (OE-Mut-Flag) was then overexpressed. Co-IP experiments were conducted using anti-Flag antibodies, and subsequent WB analysis was used to detect the expression of WASH1-Flag and p62 (n = 3). (E) MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 48 h, followed by WB analysis to detect the expression of LC3BI/II, p62, TOM20, TIM23, and COX IV (n = 3). (F) MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 24 h, followed by mt-Keima ratiometric analysis to quantify mitophagy levels (n = 4). (G) MMQ and AtT-20 cells in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 24 h, and confocal fluorescence microscopy was used to observe the co-localization of mitochondria (TOM20) and lysosomes (lysosome-associated membrane protein 1, LAMP1) (n = 3). (H–I) MMQ and AtT-20 cells with p300 overexpression and Washc1 knockout in the vector group, OE-WT-Flag group, or OE-Mut-Flag group were treated with BRC (10 μM) for 48 h, followed by flow cytometry to detect mitochondrial ROS and cell apoptosis levels (n = 3). One-way ANOVA was used for comparison among multiple groups. Data are presented as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: Rat prolactinoma cell line MMQ, growth hormone adenoma cell line GH3, and mouse corticotropin adenoma cell line AtT-20 were obtained from the American Type Culture Collection (ATCC).

Techniques: Binding Assay, Ubiquitin Proteomics, Plasmid Preparation, Knockdown, Expressing, Membrane, Knock-Out, Immunoprecipitation, Mass Spectrometry, Protein-Protein interactions, Over Expression, Mutagenesis, Co-Immunoprecipitation Assay, Fluorescence, Microscopy, Flow Cytometry, Comparison